Stockscreener 앱 받기
76.82
0.08%
0.06
시간 외 거래:
76.82
전일 마감가:
$76.76
열려 있는:
$77.1
하루 거래량:
1.29M
Relative Volume:
0.58
시가총액:
$12.69B
수익:
$943.38M
순이익/손실:
$-380.99M
주가수익비율:
-31.14
EPS:
-2.4667
순현금흐름:
$-325.67M
1주 성능:
+2.45%
1개월 성능:
+7.91%
6개월 성능:
+6.12%
1년 성능:
+170.68%
1일 변동 폭
$75.77
$77.18
1주일 범위
$74.53
$77.38
52주 변동 폭
$27.57
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
76.82 | 12.68B | 943.38M | -380.99M | -325.67M | -2.4667 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 재개 | Raymond James | Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-10-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
Ionis to hold first quarter 2026 financial results webcast - The Joplin Globe
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript - GuruFocus
Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals - Yahoo Finance
(IONS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Ionis Pharmaceuticals (IONS) Receives Outperform Rating with Ele - GuruFocus
Ionis Pharmaceuticals Inc : Raymond James Res - Moomoo
Winners Losers: Is Ionis Pharmaceuticals Inc a top pick in the sector2026 Market Outlook & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Ionis Pharmaceuticals (IONS) Receives Updated Analyst Rating fro - GuruFocus
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating - Moomoo
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com
Will Ionis Pharmaceuticals Inc benefit from sector rotation2026 Price Targets & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors - TipRanks
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewswire Inc.
Treasury Yields: Can Ionis Pharmaceuticals Inc outperform in the next rallyQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
IONS Technical Analysis & Stock Price Forecast - Intellectia AI
IONS PE Ratio & Valuation, Is IONS Overvalued - Intellectia AI
IONS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC - MarketBeat
Retinitis Pigmentosa Market to Reach US$ 26.2 Billion by 2032 - openPR.com
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmac - gurufocus.com
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmaceuticals Inc (IONS) - gurufocus.com
Devers, Ionis Pharmaceuticals EVP, sells $458,613 in IONS stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 6,193 Shares - marketbeat.com
J. Safra Sarasin Holding AG Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
ETF Watch: Can Ionis Pharmaceuticals Inc weather a recessionWeekly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Form 144 | Ionis Pharmaceuticals(IONS.US) Director Proposes to Sell 5.47 Million in Common Stocks - Moomoo
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following FDA Priority Review For Zilganersen - Sahm
FDA Priority Review Puts Ionis Zilganersen At Center Of Rare-Disease Story - Yahoo Finance
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report? - Yahoo Finance
Vanguard disaggregates holdings; reports 0 IONS shares (IONS) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Is It Time To Reassess Ionis Pharmaceuticals (IONS) After Its Strong One Year Share Price Run? - Sahm
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Ionis Cuts Tryngolza Price Ahead Of Big New Indication - insights.citeline.com
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga
Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106 - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays - MarketBeat
Barclays Raises Price Target for Ionis Pharmaceuticals (IONS) to $106 | IONS Stock News - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart
What is HC Wainwright's Estimate for IONS FY2027 Earnings? - marketbeat.com
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):